List server
Season 2 Episode
- Season 2 Challenges of the Leaders Summit on Climate: Mark Jacobson / Professor of Civil and Environmental Engineering, Stanford University
- Season 2 Tackling Climate Change: Mark Jacobson / Professor of Civil and Environmental Engineering, Stanford University
- Season 2 Vaccinations - The Global Response to COVID-19 a Year On: Akiko Iwasaki / Professor of Immunobiology, Yale University / Howard Hughes Medical Institute
- Season 2 What Will Our Post-Pandemic Future Look Like?: Akiko Iwasaki / Professor of Immunobiology, Yale University / Howard Hughes Medical Institute
- Season 2 Impacts of US Withdrawal from Afghanistan: Cheryl Benard / Political Analyst, President of Alliance for the Restoration of Cultural Heritage
- Season 2 What Does US Withdrawal Mean to People in Afghanistan?: Cheryl Benard / Political Analyst, President of Alliance for the Restoration of Cultural Heritage
- Season 2 China's Challenge to US Dominance in Space Exploration: Michio Kaku / Theoretical Physicist, Professor at The City College of New York
- Season 2 Future of Space Exploration: Michio Kaku / Theoretical Physicist, Professor at The City College of New York
- Season 2 Will the Right to Abortion Be Overturned in the U.S.?: Mary Ziegler / Professor, Florida State University
- Season 2 Power to Rollback Abortion Rights around the World: Mary Ziegler / Professor, Florida State University
- Season 2 How Do Athletes Deal with Pressure?: William Parham / Professor, Loyola Marymount University/Member of the US Olympic and Paralympic Committee's Mental Health Task Force
- Season 2 How Do We Cope with Coronavirus Variants?: Caleb Alexander / Professor of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health
- Season 2 The New Alzheimer's Drug - Are We Closer to a Cure?: Caleb Alexander / Professor of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health
- Season 2 Shohei Ohtani, Making Inroads in America: Jeff Fletcher / National Baseball Writer and Chairman of LA Chapter of the Baseball Writers Association of America
- Season 2 Tackling Gun Violence during the Pandemic: Robert Spitzer / Political Science Professor, State University of New York Cortland
- Season 2 Seeking a Breakthrough on Gun Control: Robert Spitzer / Political Science Professor, State University of New York Cortland
- Season 2 Broadway's Long-Awaited Return: Lee Seymour / Theater Producer, Writer, Senior Contributor for Forbes Magazine
- Season 2 Dealing with Afghanistan Under the Taliban: Richard Fontaine / Chief Executive Officer, Center for a New American Security
- Season 2 Reaffirming America's Credibility and Leadership: Richard Fontaine / Chief Executive Officer, Center for a New American Security
- Season 2 Is Your Child's Screen Time Too Much?: Nusheen Ameenuddin / Pediatrician, Mayo Clinic Children's Center/Chair, Council on Communications and Media, American Academy of Pediatrics
- Season 2 How Can We Adapt to Climate Change?: Alice Hill / David M. Rubenstein Senior Fellow for Energy and Environment, Council on Foreign Relations
- Season 2 Climate Change as a Global Security Threat: Alice Hill / David M. Rubenstein Senior Fellow for Energy and Environment, Council on Foreign Relations
- Season 2 Impact of Racial Diversity in Media: Eddie Glaude Jr. / Professor of African American Studies, Princeton University
- Season 2 How Should We Regulate Social Media?: Jack Balkin / Professor of Law, Yale University
- Season 2 The Rise of Big Tech and Democracy: Jack Balkin / Professor of Law, Yale University
- Season 2 Regaining US Economic Strength: Austan Goolsbee / Professor, University of Chicago Booth School
Deeper Look from New York - Season 2 Episode 13 The New Alzheimer's Drug - Are We Closer to a Cure?: Caleb Alexander / Professor of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health
0.00 48 minutes 50 million people worldwide have dementia, with 10 million new cases emerging annually. Alzheimer's disease is the most common form of dementia, but for 20-years, there have been no new drugs to tackle the disorder until now. In June, the US Food and Drug Administration approved Aducanumab, a new Alzheimer's medication. While this is a promising development, fierce debate surrounds its efficacy and approval process. FDA Advisory Committee member Dr. Alexander discusses this controversial drug.
